摘要
心脏移植是治疗终末期心脏疾病的有效手段。以钙调磷酸酶抑制剂(CsA或FK506)为基础的免疫抑制治疗是心脏移植术后最常用的免疫抑制方案,许多心脏移植受者在移植前或/和移植后同时使用单克隆抗体进行诱导治疗。雷帕霉素和Everolimus等新型免疫抑制剂在有效抑制急性排斥反应的同时还可预防移植物心血管病变,显示出较好的应用前景。应用免疫学指标、心肌标记物和其它血清标记物等相对无创的指标预测和估计排斥反应的发生及其程度,有助于尽早发现和控制移植排斥反应,以提高心脏移植的效果。
Cardiac transplantation is an effective therapeutic method for terminal-stage heart diseases. The immunosuppressive treatment based on calcineurin inhibitors （CsA and FK506） is most commonly used, monoclonal antibodies are also used in some recipients as induction therapy before and/or after transplantation. Some new immunosuppressive drugs, such as Rapamycin and Everolimus, can not only inhibit the acute transplant rejection but also prevent cardiac vasculopathy. The application of some relatively non-traumatic tests, such as immunological indexes, cardiac markers and other serological parameters, are helpful for diagnosis and preventing postcardiac transplant rejection at early stage and improving the result of cardiac transplantation.
出处
《中国胸心血管外科临床杂志》
CAS
2007年第1期51-56,共6页
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
关键词
心脏移植
免疫抑制
免疫监测
Cardiac transplantation
Immunosuppression
Immunological monitoring
